
Investing.com —— 据《金融时报》周日报道,援引知情人士消息,强生公司(纽约证券交易所代码:JNJ)正在就收购私营眼科疾病药物开发商 Ollin Biosciences 进行深度谈判,交易对价最高可达 34 亿美元。
Investing.com-- Johnson & Johnson (NYSE:JNJ) is in advanced talks to acquire privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.
报道称,该交易可能包含 22 亿美元的首付现金支付以及最高 12 亿美元的里程碑付款,但谈判仍有可能破裂。
The deal could involve an upfront cash payment of $2.2 billion and up to $1.2 billion in milestone payments, although discussions could still fall apart, the report said.

Ollin 由 Arch Venture Partners 和 Mubadala Capital 支持,正在开发 OLN324,这是一种针对湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的药物,这两种疾病是导致严重视力丧失的主要原因。该疗法预计将进入晚期临床试验。
Ollin, backed by Arch Venture Partners and Mubadala Capital, is developing OLN324, a drug targeting wet age-related macular degeneration and diabetic macular oedema, two leading causes of severe vision loss. The treatment is expected to enter late-stage clinical trials.




此次收购将扩大强生在视网膜疾病治疗领域的布局,尽管其拥有隐形眼镜业务,但在这一领域的涉足有限。
The acquisition would expand J&J's presence in retinal disease treatments, an area where it has limited exposure despite its contact lens business.
据投资银行 Stifel 统计,《金融时报》报道,今年迄今已有 46 家估值超过 10 亿美元的生物技术公司被出售,超过了此前 35 家的年度纪录,生物技术收购迎来创纪录的一年,这笔潜在交易正是在此背景下出现的。
The potential deal comes amid a record year for biotech acquisitions, with 46 companies valued at more than $1 billion sold so far, surpassing the previous annual record of 35, according to investment bank Stifel, the FT reported.
强生洽谈以 34 亿美元收购眼科生物技术公司 Ollin,《金融时报》报道
J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports